3Woodward DF, Andrew SW, Burk RM, Garst ME, inventors;Allergan, Inc, assignee. Non - acidic cytopentane heptanoic acid, 2 - cycloalkyl or arylalkyl derivatives as therapeutic agents.US Patent 5352708. Oct 4, 1994.
4Yu M, lves D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anadamide by cyclooxygenase - 2. J Biol Chem, 1997, 272:21181-21186.
5Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther, 2002, 18 (4):313-324.
6Woodward DF, Krauss AH - P, Chen J Lai RK0 Spada CS,Burke RM, et al. The Pharmacology of bimatoprost (Lumigan^TM). Surv. Ophthalmol, 2001, (Suppl) 45:337-345.
7Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K,Vandenburgh AM. Effects of AGN 192024, a new ocular hypotenslve agent, on aqueous dynamics. Am J Ophthalmol, 2001,131 (1): 19-24.
8Herndon LW, Asrani SG, Williams GH, Challa P, Lee PP.Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. Arch Ophthalmol, 2002, 120(6): 847-849.
9BrandtJD, VanDenburgh AM, Chen K, Whitcup SM; Bimatoprost Study Group. Comparison of once - or twlee - daily bimatoprost with-twice - daily timolol in patients with elevated IOP a 3 -month clinical trial. Ophthalmology, 2001, 108 (6): 1023-1031 ; discussion 1032.
10Laibovitz RA, VanDenburgh AM, Felix C, David R, Batoosingh A, Rosenthal A, Cheetham J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management.Arch Ophthalmol, 2001, 119 (7): 994-1000.
同被引文献13
1Woodward DF, Krauss AHP, Chen J, et al. The pharmacol- ogy of bimatoprost (Lumigan). Surv Ophthalmol, 2001,45 Suppl 4 :S337-345.
2Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctua- tions in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma, 2000,9 : 134-142.
4Woodward DF,Krauss AH,Chen J,et al.The pharmacology of bimatoprost(Lumigan).Surv Ophthalmol,2001,45(Supp14):S337-345.
5Asrani S,Zeimer R,Wilensky J,et al.Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma.J Glaucoma,2000,9:134-142.
6Mao LK,Stewart WC,Shields MB.Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma.Am J Ophthalmol,1991,111:51-55.
